

**Appendix Table F67. Outcomes after intravesical 100ml of 50nM-single dose injection of resiniferatoxin vs. placebo, individual RCTs**

Reference	Active N	Control N	Outcome	Active mean+/- standard deviation	Control mean+/- standard deviation	Mean difference	Lower 95% CI	Upper 95% CI
Rios, 2007 <sup>364</sup>	34	24	General health perception	35.3+/-13.92	44.8+/-23.29	-9.50	-19.93	0.93
Rios, 2007 <sup>364</sup>	34	24	Incontinence impact	61.8+/-33.97	66.7+/-36.78	-4.90	-23.53	13.73
Rios, 2007 <sup>364</sup>	34	24	Role limitations	50.5+/-35.65	51.5+/-35.86	-0.96	-19.65	17.73
Rios, 2007 <sup>364</sup>	34	24	Physical limitations	47.1+/-37.03	46.5+/-38.06	0.53	-19.14	20.20
Rios, 2007 <sup>364</sup>	34	24	Social limitations	24.2+/-29.27	37.9+/-30.83	-13.74	-29.52	2.04
Rios, 2007 <sup>364</sup>	34	24	Personal relationships	32.7+/-45.77	35.4+/-39.85	-2.75	-24.91	19.41
Rios, 2007 <sup>364</sup>	34	24	Emotions	44.4+/-36.60	54.6+/-35.12	-10.19	-28.87	8.49
Rios, 2007 <sup>364</sup>	34	24	Sleep and energy	28.9+/-23.68	38.2+/-31.27	-9.28	-24.11	5.55
Rios, 2007 <sup>364</sup>	34	24	Symptom severity	15.5+/-10.05	10.1+/-10.98	5.39	-0.15	10.93
Reference	Active N	Control N	Outcome	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	
Rios, 2007 <sup>364</sup>	34	24	Hypogastric pain	12/34	4/24	2.12 (0.78;5.78)	0.19 (-0.03;0.41)	
Rios, 2007 <sup>364</sup>	34	24	Dysuria	15/34	6/24	1.76 (0.80;3.89)	0.19 (-0.05;0.43)	
Rios, 2007 <sup>364</sup>	34	24	Minor hematuria	1/34	3/24	0.24 (0.03;2.13)	-0.10 (-0.24;0.05)	